Primary analysis of a phase II study of atezolizumab plus bevacizumab for TACE-unsuitable patients with tumor burden beyond up-to-seven criteria in intermediate-stage hepatocellular carcinoma: REPLACEMENT study

被引：0
|
作者：
Ueshima, Kazuomi
Kudo, Masatoshi
Tsuchiya, Kaoru
Kato, Naoya
Yamashita, Tatsuya
Shimose, Shigeo
Numata, Kazushi
Kodama, Yuzo
Tanaka, Yasuhito
Kuroda, Hidekatsu
Itoh, Shinji
Aikata, Hiroshi
Hiraoka, Atsushi
Moriguchi, Michihisa
Wada, Yoshiyuki
Nakao, Kazuhiko
Tateishi, Ryosuke
Ogasawara, Sadahisa
Yamamoto, Kouji
Ikeda, Masafumi
机构：
[1] Kindai Univ, Fac Med, Osaka, Osaka, Japan
[2] Kindai Univ, Fac Med, Osaka, Japan
[3] Musashino Red Cross Hosp, Dept Gastroenterol & Hepatol, Musashino, Japan
[4] Chiba Univ, Grad Sch Med, Dept Gastroenterol, Chuo Ku, Chiba, Japan
[5] Kanazawa Univ Hosp, Kanazawa, Japan
[6] Kurume Univ Hosp, Kurume, Japan
[7] Yokohama City Univ, Med Ctr, Yokohama, Japan
[8] Kobe Univ, Div Gastroenterol, Dept Internal Med, Grad Sch Med, Kobe, Japan
[9] Kumamoto Univ, Dept Gastroenterol & Hepatol, Fac Life Sci, Kumamoto, Japan
[10] Iwate Med Univ, Sch Med, Div Gastroenterol & Hepatol, Dept Internal Med, Yahaba, Japan
[11] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka, Japan
[12] Hiroshima Prefectural Hosp, Dept Gastroenterol, Hiroshima, Japan
[13] Ehime Prefectural Cent Hosp, Gastroenterol Ctr, Matsuyama, Japan
[14] Kyoto Prefectural Univ Med, Kyoto, Japan
[15] Natl Hosp Org, Kyushu Med Ctr, Fukuoka, Japan
[16] Nagasaki Univ, Dept Gastroenterol & Hepatol, Grad Sch Biomed Sci, Nagasaki, Japan
[17] Univ Tokyo Hosp, Bunkyo Ku, Tokyo, Japan
[18] Chiba Univ, Grad Sch Med, Chiba, Japan
[19] Yokohama City Univ, Dept Biostat, Sch Med, Yokohama, Japan
[20] Natl Canc Ctr Hosp East, Dept Hepatobiliary & Pancreat Oncol, Kashiwa, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4125
引用
收藏
页数：1
相关论文
共 46 条
  • [1] REPLACEMENT trial in progress: Combination therapy with atezolizumab plus bevacizumab for TACE unsuitable patients with beyond up-to-seven criteria in intermediate stage hepatocellular carcinoma: A phase II study.
    Ueshima, Kazuomi
    Kudo, Masatoshi
    Yamanaka, Takeharu
    Aikata, Hiroshi
    Yamashita, Tatsuya
    Ikeda, Masafumi
    Tateishi, Ryosuke
    Moriguchi, Michihisa
    Hiraoka, Atsushi
    Tsuchiya, Kaoru
    Ogasawara, Sadahisa
    Mochida, Satoshi
    Miyayama, Shiro
    Hasegawa, Kiyoshi
    Yoshimura, Kenichi
    Takehara, Tetsuo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Final analysis of the REPLACEMENT study: a phase II study of atezolizumab plus bevacizumab (atezo plus bev) for patients (pts) with Transcatheter arterial chemoembolization (TACE)-unsuitable intermediate-stage hepatocellular carcinoma (HCC) beyond the up-to-seven criteria
    Yamashita, T.
    Ueshima, K.
    Tsuchiya, K.
    Kato, N.
    Shimose, S.
    Numata, K.
    Kodama, Y.
    Ohkawa, K.
    Kuzuya, T.
    Ikeda, M.
    Kooka, Y.
    Aikata, H.
    Hiraoka, A.
    Moriguchi, M.
    Fujiwara, K.
    Suda, G.
    Mochida, S.
    Ogasawara, S.
    Yamamoto, K.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2024, 35 : S1483 - S1484
  • [3] Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma
    Kudo, Masatoshi
    LIVER CANCER, 2022, 11 (05) : 399 - 406
  • [4] TACE plus lenvatinib and tislelizumab for intermediate-stage hepatocellular carcinoma beyond up-to-11 criteria: a multicenter cohort study
    Chen, Song
    Tang, Shuangyan
    Shi, Feng
    Cai, Hongjie
    Wu, Zhiqiang
    Wang, Liguang
    Ma, Ping
    Zhou, Yuanmin
    Mai, Qicong
    Wang, Fan
    Lai, Jiaming
    Chen, Xiaoming
    Chen, Huanwei
    Guo, Wenbo
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [5] Initial lenvatinib therapy with no prior TACE in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and Child-Pugh A liver function: A proof-of-concept study
    Kudo, Masatoshi
    Ueshima, Kazuomi
    Chan, Stephen Lam
    Aoki, Tomoko
    Hagiwara, Satoru
    Minami, Yasunori
    Ida, Hiroshi
    Takenaka, Mamoru
    Watanabe, Tomohiro
    Morita, Masahiro
    Ogawa, Chikara
    Wada, Yoshiyuki
    Ikeda, Masafumi
    Ishii, Hiroshi
    Izumi, Namiki
    Hiraoka, Atsushi
    Aikata, Hiroshi
    Nishida, Naoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [6] Redefining Tumor Burden in Patients with Intermediate-Stage Hepatocellular Carcinoma: The Seven-Eleven Criteria
    Hung, Ya-Wen
    Lee, I-Cheng
    Chi, Chen-Ta
    Lee, Rheun-Chuan
    Liu, Chien-An
    Chiu, Nai-Chi
    Hwang, Hsuen-En
    Chao, Yee
    Hou, Ming-Chih
    Huang, Yi-Hsiang
    LIVER CANCER, 2021, 10 (06) : 629 - 640
  • [7] Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study
    Kudo, Masatoshi
    Ueshima, Kazuomi
    Chan, Stephan
    Minami, Tomohiro
    Chishina, Hirokazu
    Aoki, Tomoko
    Takita, Masahiro
    Hagiwara, Satoru
    Minami, Yasunori
    Ida, Hiroshi
    Takenaka, Mamoru
    Sakurai, Toshiharu
    Watanabe, Tomohiro
    Morita, Masahiro
    Ogawa, Chikara
    Wada, Yoshiyuki
    Ikeda, Masafumi
    Ishii, Hiroshi
    Izumi, Namiki
    Nishida, Naoshi
    CANCERS, 2019, 11 (08)
  • [8] Combination Therapy With Lenvatinib and Radiofrequency Ablation for Patients With Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh Class A Liver function: A Pilot Study
    Wang, Feiqian
    Numata, Kazushi
    Komiyama, Satoshi
    Miwa, Haruo
    Sugimori, Kazuya
    Ogushi, Katsuaki
    Moriya, Satoshi
    Nozaki, Akito
    Chuma, Makoto
    Ruan, Litao
    Maeda, Shin
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [9] Subclassification of patients with intermediate-stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinoma using the up-to-seven criteria and serum tumor markers
    Kimura, Haruki
    Ohkawa, Kazuyoshi
    Miyazaki, Masanori
    Sakakibara, Mitsuru
    Imanaka, Kazuho
    Tamura, Takeshi
    Sueyoshi, Hironari
    Takada, Ryoji
    Fukutake, Nobuyasu
    Uehara, Hiroyuki
    Ashida, Reiko
    Ioka, Tatsuya
    Nakazawa, Tetsuro
    Nakanishi, Katsuyuki
    Katayama, Kazuhiro
    HEPATOLOGY INTERNATIONAL, 2017, 11 (01) : 105 - 114
  • [10] Subclassification of patients with intermediate-stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinoma using the up-to-seven criteria and serum tumor markers
    Haruki Kimura
    Kazuyoshi Ohkawa
    Masanori Miyazaki
    Mitsuru Sakakibara
    Kazuho Imanaka
    Takeshi Tamura
    Hironari Sueyoshi
    Ryoji Takada
    Nobuyasu Fukutake
    Hiroyuki Uehara
    Reiko Ashida
    Tatsuya Ioka
    Tetsuro Nakazawa
    Katsuyuki Nakanishi
    Kazuhiro Katayama
    Hepatology International, 2017, 11 : 105 - 114
12345